Guggenheim Names Top Stock Pick in Biotech Sector
- Investing.com
Metrics to compare | ABVX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABVXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −17.7x | −2.6x | −0.4x | |
PEG Ratio | 0.27 | −0.08 | 0.00 | |
Price/Book | 19.4x | 0.1x | 2.6x | |
Price / LTM Sales | 1,519.2x | 14.6x | 3.1x | |
Upside (Analyst Target) | 74.2% | 176.3% | 55.6% | |
Fair Value Upside | Unlock | 3.9% | 7.8% | Unlock |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.